

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		Attorney Docket No. <b>056291-5292</b>	Application No. <b>10/581,279</b>
		Applicants: <b>James MCCABE</b>	
PTO Form 1449 November 1, 2007		1624	Filing Date: <b>June 1, 2006</b>
		Group Art Unit: <b>XXXXXX</b>	

**U.S. PATENT DOCUMENTS**

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	US 2002/0177601	November 28, 2002	Himmelsbach et al.			
2.	US 5,409,930	April 25, 1995	Spada et al.			
3.	US 5,411,963	May 2, 1995	Dreilcorn et al.			
4.	US 5,480,883	January 2, 1996	Spada et al.			
5.	US 5,646,153	July 8, 1997	Spada et al.			
6.	US 5,710,158	January 20, 1998	Myers et al.			
7.	US 5,714,493	February 3, 1998	Myers et al.			
8.	US 5,721,237	February 24, 1998	Myers et al.			
9.	US 5,736,534	April 7, 1998	Arnold et al.			
10.	US 5,859,009	January 12, 1999	Schaper et al.			
11.	US 6,046,206	April 4, 2000	Pamukcu et al.			
12.	US 6,057,320	May 2, 2000	Spada et al.			
13.	US 6,153,617	November 28, 2000	Bridges			
14.	US 6,162,804	December 19, 2000	Bilodeau et al.			
15.	US 6,225,318	May 1, 2001	Sobolov-Jaynes et al.			
16.	US 6,531,491	March 11, 2003	Kania et al.			
17.	US 6,645,969	November 11, 2003	Myers et al.			
18.	US Re. 36,256	July 20, 1999	Spada et al.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

**FOREIGN PATENT DOCUMENTS**

	Document No.	Date	Country	Class	Sub-Class	Translation
19.	DE 19614718	October 16, 1997	Germany			
20.	EP 0326330	August 2, 1989	Europe			
21.	EP 0602851	June 22, 1994	Europe			
22.	EP 0837063	April 22, 1998	Europe			
23.	EP 1029853	August 23, 2000	Europe			
24.	GB 2345486	July 12, 2000	United Kingdom			
25.	WO 87/04321	July 30, 1987	WIPO			
26.	WO 92/20642	November 26, 1992	WIPO			
27.	WO 95/15758	June 15, 1995	WIPO			
28.	WO 95/19169	July 20, 1995	WIPO			
29.	WO 95/23141	August 31, 1995	WIPO			
30.	WO 95/24190	September 14, 1995	WIPO			
31.	WO 96/29301	September 26, 1996	WIPO			
32.	WO 96/39145	December 12, 1996	WIPO			
33.	WO 97/03069	January 30, 1997	WIPO			
34.	WO 97/17329	May 15, 1997	WIPO			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

Examiner		Date Considered
	/Tamthom Truong/	06/09/2009

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All foreign documents need names.

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)			Attorney Docket No. <b>056291-5292</b>	Application No. <b>10/581,279</b>			
			Applicants: <b>James MCCABE</b>				
<b>PTO Form 1449</b> November 1, 2007			1624				
			Filing Date: <b>June 1, 2006</b>	Group Art Unit: <b>XXXXXX</b>			
<b>U.S. PATENT DOCUMENTS</b>							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
<b>ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./</b>							
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document No.	Date	Country	Class	Sub-Class	Translation
35.		WO 97/22596	June 26, 1997	WIPO			
36.		WO 97/30034	August 21, 1997	WIPO			
37.		WO 97/42187	November 13, 1997	WIPO			
38.		WO 98/02434	January 22, 1998	WIPO			
39.		WO 98/54093	December 3, 1998	WIPO			
40.		WO 99/06396	February 11, 1999	WIPO			
41.		WO 99/10349	March 4, 1999	WIPO			
42.		WO 99/21859	May 6, 1999	WIPO			
43.		WO 99/35132	July 15, 1999	WIPO			
.	44.	WO 99/35146	July 15, 1999	WIPO			
	45.	WO 00/06554	February 10, 2000	WIPO			
	46.	WO 00/12497	March 9, 2000	WIPO			
	47.	WO 00/44728	August 3, 2000	WIPO			
	48.	WO 00/55141	September 21, 2000	WIPO			
	49.	WO 01/02369	January 11, 2001	WIPO			
	50.	WO 01/29025	April 26, 2001	WIPO			
<b>ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./</b>							
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	51.	Bridges et al. "Enantioselective Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase by a 4-(a-Phenethylamino)quinazolines" Bioorganic & Medicinal Chemistry 3(12):1651-1656 (1995).					
	52.	Gazit et al. "Tyrophostins IV-Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4-Anilidoquinazolines" Bioorganic & Medicinal Chemistry 4(8): 1203-1207 (1996) .					
	53.	Gibson et al., "Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines" Bioorganic & Medicinal Chemistry 7(21):2723-2728 (1997) .					
	54.	Hara et al., "On the Amination of Azaheterocycles. A New Procedure for the Introduction of an Amino Group (1)" J. Heterocyclic Chem. 19:1285-1287 (1982) .					
	55.	Hennequin et al., "Design and Structure Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors" Journal of Medicinal Chemistry, American Chemical Society 42: 5369-5389 (1999) .					
	56.	Karminski et al., Chemical Abstracts, Vol. 100: 54492 (1984)					
	57.	Karminski et al. "The Synthesis of Some Quinazoline Derivatives and Their Biological Properties" J. Environ. Sci. Health B18: 599-610 (1983) .					
	58.	Sinyak et al., Chemical Abstracts, Vol. 140: 199594 (1986).					
	59.	Sinyak et al. "Synthesis and Biological Properties of Derivatives of 4-Hetarylmercaptoquinazoline" Zaporozh'e Medical Institute pp. 103-106, translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 20, No. 2, Feb. 1986, 168-171					
Examiner <i>/Tamthom Truong/</i>			Date Considered <i>06/09/2009</i>				
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Crossed out reference has no copy  
provided. All foreign documents need  
names.